18:51 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Esperion combo lowers LDL-C in Phase III for high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
19:45 , Aug 27, 2018 |  BC Extra  |  Clinical News

Esperion combo lowers LDL-C in high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
15:29 , May 25, 2018 |  BC Week In Review  |  Clinical News

Esperion's hypercholesterolemia candidate meets in Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily 180 mg oral bempedoic acid (ETC-1002) met the primary endpoint of reducing LDL-C from baseline to week 12 vs. placebo (23% vs. 1%, p<0.001) in the Phase III CLEAR...
16:09 , May 4, 2018 |  BC Week In Review  |  Clinical News

Esperion reports Phase III data for hypercholesterolemia candidate

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) met the primary safety endpoint and key secondary efficacy endpoint in the Phase III CLEAR Harmony (1002-040) trial to treat high-risk atherosclerotic cardiovascular disease (ASCVD) patients with...
16:51 , May 2, 2018 |  BC Extra  |  Clinical News

Esperion falls on Phase III data for hypercholesterolemia candidate

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) met the primary safety endpoint and key secondary efficacy endpoint in the Phase III CLEAR Harmony (1002-040) trial to treat high-risk atherosclerotic cardiovascular disease (ASCVD) patients with...
18:58 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Esperion reports first Phase III hypercholesterolemia data

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily oral bempedoic acid (ETC-1002) met the primary endpoint in the Phase III CLEAR Tranquility (1002-048) trial to treat hypercholesterolemia in patients with atherosclerotic cardiovascular disease (ASCVD). The company also...
00:08 , Mar 8, 2018 |  BC Extra  |  Clinical News

Esperion reports first Phase III hypercholesterolemia data

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily oral bempedoic acid (ETC-1002) met the primary endpoint in the Phase III CLEAR Tranquility (1002-048) trial to treat hypercholesterolemia in patients with atherosclerotic cardiovascular disease (ASCVD). The company also...
17:22 , Mar 2, 2018 |  BC Week In Review  |  Company News

Esperion prices LDL-C candidate

Esperion Therapeutics Inc. (NASDAQ:ESPR) said it plans to price hypercholesterolemia candidate bempedoic acid (ETC-1002) at about $10 per day. The company said it is targeting patients who need less than 30% lowering in LDL-C and...
21:54 , Jan 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Tissue damage Mouse studies suggest promoting ACLY expression could help treat skeletal muscle damage. In a mouse model of chemical-induced skeletal muscle damage, intramuscular injection of ACLY encoded in an adeno-associated viral (AAV) vector increased...
16:08 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Esperion's bempedoic acid combo meets in Phase II for hypercholesterolemia

Esperion Therapeutics Inc. (NASDAQ:ESPR) reported top-line data from the Phase II 1002-038 trial in 63 patients with hypercholesterolemia showing that the once-daily combination of 180 mg bempedoic acid (ETC-1002)/10 mg Zetia ezetimibe plus 20 mg...